Glenmark Pharmaceuticals Ltd, a pharmaceutical company, today announced that its subsidiary, Glenmark Specialty SA has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC for commercialising its novel nasal spray Ryaltris™ in United States of America.